Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201426
Title: | HPV self-sampling among cervical cancer screening users in Spain: A randomized clinical trial of on-site training to increase the acceptability |
Author: | Ibáñez, Raquel Roura Fornells, Esther Acera Pérez, Amèlia Andújar, Miguel Pavón Ribas, Miquel Àngel Bruni, Laia Sanjosé, Silvia de |
Keywords: | Papil·lomavirus Medicina preventiva Papillomaviruses Preventive medicine |
Issue Date: | 1-Aug-2023 |
Publisher: | Elsevier BV |
Abstract: | A randomized clinical trial was conducted to compare the impact of two different instructions on vaginal selfsampling in its acceptability and willingness for future screening rounds among women attending cervical cancer screening (CCS).From November 2018 to May 2021, women aged 30-65 living in Spain attending CCS were randomized 1:1 in two arms. In the On-site training arm (TRA), women took a self-sample at the primary health care centre following provider's instructions. In the No on-site training arm (NO-TRA) women only received instructions to take self-sample at home. All women had to return a new sample collected at home one month after the baseline visit and an acceptability questionnaire. The proportion of self-samples returned, and acceptability was computed by the study arm.A total of 1158 women underwent randomization, 579 women per arm. At follow-up, women in TRA were more likely to return the home sample than women in the NO-TRA (82.4% and 75.5% respectively; p = 0.005). Over 87% of all participants favoured home-based self-sampling approach for future CCS, similar by arm. Over 80% of women in both arms chose to collect and return the self-sample at a health centre or pharmacy.Home-based self-sampling was a highly accepted strategy for CCS in Spain. Trying it first with prior on-site training at the health centre significantly increased the sample's return suggesting that a provider's supervision raised confidence and adherence. It is an option to consider when moving to self-sampling in established CCS. Preferred delivery sites most likely contextual.Registration on ClinicalTrials.gov: NCT05314907. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.ypmed.2023.107571 |
It is part of: | Preventive Medicine, 2023, vol. 173, |
URI: | http://hdl.handle.net/2445/201426 |
Related resource: | https://doi.org/10.1016/j.ypmed.2023.107571 |
ISSN: | 1096-0260 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0091743523001512-main.pdf | 1.93 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License